Prosensa upgraded to Outperform from Neutral at Wedbush Wedbush upgraded Prosena following new encouraging subset data analysis of lead drug drisapersen and full ownership potential following termination of its partnership with GlaxoSmithKline. Price target raised to $12 from $7.
Prosensa upgraded to Overweight from Underweight at JPMorgan JPMorgan upgraded Prosensa two notches to Overweight citing a favorable risk/reward around the potential approval of Drisapersen for Duchenne muscular dystrophy. The firm believes regulatory risk for the drug has been significantly reduced in both the U.S. and Europe. JPMorgan raised its price target for shares to $18 from $4.40.